SAB BIO

Executive Summary

SAB BIO is a private, clinical-stage biotechnology company headquartered in San Diego, California, dedicated to developing disease-modifying therapies for autoimmune diseases, with a primary focus on Type 1 Diabetes (T1D). The company's lead asset, SAB-142, aims to preserve insulin-producing beta cell function by addressing the underlying immune cause of T1D, rather than merely managing symptoms like current standard therapies. Founded in 2018, SAB BIO is positioned in the competitive autoimmune space, targeting a large unmet need for treatments that can alter disease progression. Although the company has not disclosed specific financial details or pipeline timelines, its focus on a novel mechanism for T1D differentiates it from symptomatic approaches. SAB BIO remains privately held, and its clinical-stage status suggests ongoing or imminent clinical trials to evaluate SAB-142's safety and efficacy.

Upcoming Catalysts (preview)

• TBDSeries A Financing Round70% success
• TBDPhase 1/2 Clinical Data Readout for SAB-14250% success
• TBDRegulatory Designation (e.g., Fast Track or Orphan Drug Status)40% success